Screening of tuberculosis before biologics

Medecine et Maladies Infectieuses

Volumn 42, Issue 1, 2012, Pages 1-4

  Mrozek, N ^a   Pereira, B ^b   Soubrier, M ^a   Gourdon, F ^a   Laurichesse, H ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Biologics; Chronic inflammatory rheumatisms; IGRA; ITT; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; TOCILIZUMAB; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ANAMNESIS; BIOLOGICAL THERAPY; BLOOD EXAMINATION; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; FRANCE; HUMAN; PHYSICAL EXAMINATION; PROTEIN DETERMINATION; REVIEW; RHEUMATIC FEVER; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPONDYLOARTHROPATHY; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BCG VACCINE; BIOLOGICAL THERAPY; DISEASE SUSCEPTIBILITY; EUROPE; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FRANCE; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855860790     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.08.002     Document Type: Review

References (21)

1. Fautrel B., Pham T., Mouterde G., et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007, 74:627-637.
2. Pham T., Claudepierre P., Constantin A., et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010, 77:S3-S100.
3. Pham T., Claudepierre P., Constantin A., et al. Abatacept therapy and safety management. Joint Bone Spine 2009, 76:S3-S55.
4. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement. Eur Respir J 2010. doi:10.1183/09031936.00028510.
5. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
6. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
7. Diel R., Goletti D., Ferrara g, et al. Interferon-g release assays for the diagnosis of latent M tuberculosis infection: q systematic review and meta-analysis. Eur Resp Soc 2011, 37:88-99.
8. Chang K.C., Leung C.C. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax 2010, 65:271-276.
9. Mori T., Sakatani M., Yamagishi F., Takashima T., et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004, 170:59-64.
10. Dewan P.K., Grinsdale J., Kawamura L.M. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 2007, 44:69-73.
11. Mazurek G.H., Weis S.E., Moonan P.K., et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 2007, 45:837-845.
12. Soysal A., Torun T., Efe S., Gencer H., Tahaoglu K., Bakir M. Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M. tuberculosis infection. Int J Tuberc Lung Dis 2008, 12:50-56.
13. Domínguez J., Ruiz-Manzano J., De Souza-Galvão M., et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 2008, 15:168-171.
14. Bartu V., Havelkova M., Kopecka E. QuantiFERON-TB Gold in the diagnosis of active tuberculosis. J Int Med Res 2008, 36:434-437.
15. Kobashi Y., Mouri K., Yagi S., et al. Clinical utility of a T cell-based assay in the diagnosis of extrapulmonary tuberculosis. Respirology 2009, 14:276-281.
16. Kobashi Y., Mouri K., Yagi S., et al. Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis. Chest 2008, 133:1196-1202.
17. Kobashi Y., Mouri K., Yagi S., et al. Usefulness of the QuantiFERON TB-2G test for the differential diagnosis of pulmonary tuberculosis. Intern Med 2008, 47:237-243.
18. Kobashi Y., Mouri K., Yagi S., et al. Clinical evaluation for diagnosing active TB disease and transitional change of two commercial blood tests. Scand J Infect Dis 2008, 40:629-634.
19. van Zyl-Smit R.N., Zwerling A., Dheda K., Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009, 4(12):e8517.
20. Bray M.G., Poulain C., Dougados M., Gossec L. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine 2010, 77(2):135-141.
21. Mariette X., Lioté F., Goupille P., et al. Le remplacement de l'intradermo réaction (ITT) à The tuberculine par les tests sanguins spécifiques permet de diviser par deux The fréquence de The tuberculose (TB) latente résultats de l'étude ETAT chez 396patients avant mise sous anti-TNF. Rev Rhum 2010, 77:A37-A38.